Paf‐induced release of spasmogens from guinea‐pig lungs
Open Access
- 1 January 1989
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 96 (1) , 153-162
- https://doi.org/10.1111/j.1476-5381.1989.tb11795.x
Abstract
1 The injection of platelet activating factor (Paf; 250 ng), leukotriene B4 (LTB4; 50 ng) and leukotriene D4 (LTD4; 10 ng) elicited contractions of strips of guinea-pig trachea, bronchus and lung parenchyma. 2 When the effluent of perfused guinea-pig lungs was superfused over strips of guinea-pig trachea, bronchus and parenchyma, the intra-arterial injection of Paf (250 ng) caused the release of spasmogen(s) which contracted all three tissues. 3 The infusion of indomethacin (10 μg ml−1) into the pulmonary artery and over the assay tissues inhibited the responses of the tissues to the effluent of the lungs stimulated by Paf (250 ng) and LTB4 (50 ng). However, treating only the assay tissues with indomethacin (10 μg ml−1) did not block the contractile responses to the effluent of the lungs stimulated with LTB4 or Paf. stimulated with Paf. 4 Pretreatment of the lungs with indomethacin (10 μg ml−1) or aspirin (30 μg ml−1) for 30 min, washing them out and suspending them over the assay tissues did not block the release of spasmogens elicited by Paf but appeared to inhibit the release of cyclo-oxygenase products. 5 The infusion of two lipoxygenase inhibitors, nordihydroguaiaretic acid (NDGA; 1 μg ml−l) and L-655,240 (1 μg ml−1), into the pulmonary artery completely blocked the release of spasmogen(s) from the perfused lungs. 6 The slow reacting substance of anaphylaxis (SRS-A) antagonist, FPL-55712 (10 ng ml−1), did not block the responses of the tissues to the spasmogen(s) released by Paf. 7 The infusion of the Paf antagonist BN-52021 (30 μg ml−1) into the pulmonary artery completely abolished the release of spasmogen(s) induced by Paf. 8 These data suggest that a lipoxygenase product, possibly LTB4, could be responsible for the spasmogenic activity released by the lungs following Paf stimulation. Cyclo-oxygenase products released following Paf stimulation appear to result from the initial LTB4 generation.This publication has 20 references indexed in Scilit:
- Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpropanoic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonistEuropean Journal of Pharmacology, 1987
- Comparative effects of platelet activating factor, leukotriene D4 and histamine on guinea pig trachea, bronchus and lung parenchymaProstaglandins, 1987
- Desensitization to PAF-induced bronchoconstriction and to activation of alveolar macrophages by repeated inhalations of PAF in the guinea pigBiochemical and Biophysical Research Communications, 1985
- Paf-acether: a mediator of inflammation and asthmaTrends in Pharmacological Sciences, 1984
- Dependency of the Paf-acether induced bronchospasm on the lipoxygenase pathway in the guinea-pigProstaglandins, 1983
- Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes.Journal of Clinical Investigation, 1982
- Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of “platelet-activating factor” (PAF-acether)European Journal of Pharmacology, 1982
- Evidence for a mediator role of thromboxane A2 in the myotropic action of leukotriene B4 (LTB4) on the guinea-pig lungProstaglandins, Leukotrienes and Medicine, 1982
- The action of leukotriene B4 (LTB4) on the lungProstaglandins and Medicine, 1980
- Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivativesEuropean Journal of Pharmacology, 1980